Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

NHS England has announced a programme to provide NHS staff with evidence-based digital programmes to protect their mental health during the COVID-19 response. The apps are designed to help maintain healthy sleep, and reduce anxiety.

Sleepio is an automated digital self-help app based on cognitive behavioural therapy for insomnia. It was built by Colin Espie, Professor of Sleep Medicine at the Nuffield Department of Clinical Neurosciences and Co-Founder of digital therapeutics company Big Health. Subsequent research by Espie and his team has demonstrated the efficacy and safety of Sleepio, and provided a platform for recognition of the value of digital therapeutics more widely in the NHS and other workplaces internationally.

Fifteen NHS trusts and six GP practices have already rolled out access to Sleepio and Daylight, an app designed to help with worry and anxiety. These apps have now been made freely available to all NHS employees across the country in partnership with NHS England.

Professor Colin Espie has praised NHS England’s quick response in protecting the mental health of NHS staff as well as their physical health during the pandemic. He said: ‘I’m honoured that Big Health is able to support our colleagues in the NHS to help safeguard their mental health during these most challenging of times. NHS staff are working under enormous pressure while also experiencing significant changes to their lives at home as a result of COVID-19.’

To learn how to gain access to Daylight and Sleepio for your staff, please email ceo@bighealth.com

Similar stories

New WA Handley Chair of Psychiatry Appointed

Strategic Developments

Professor John Geddes has been appointed to the WA Handley Professorship of Psychiatry and will take up this post in November 2021.

Investigating New Treatment for Schizophrenia

Research Highlights Strategic Developments

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim has been announced to investigate a new drug target for the treatment of schizophrenia.

Retirement of Professor Peter Brown

Strategic Developments

This month sees the retirement of Professor Peter Brown as Director of the Medical Research Council Brain Network Dynamics Unit at the University of Oxford.

The ALBA Declaration

Strategic Developments

Improving Equality, Diversity and Inclusiveness.

Recognition of Distinction Awards 2020

Awards and Honours Strategic Developments

It is a great pleasure to announce that a number of Neuroscience researchers have been successful in the recent assessment process for the conferment of the title of full Professor.

Ambitious Oxford initiative launched to address graduate under-representation

Strategic Developments

Oxford University and its colleges have announced a major new scholarship scheme for black graduate students as part of a programme to transform its graduate population by creating more funding opportunities for under-represented groups.